Stockscreener 앱 받기
0.8398
1.99%
-0.0203
전일 마감가:
$0.8601
열려 있는:
$0.88
하루 거래량:
226.91K
Relative Volume:
2.70
시가총액:
$10.56M
수익:
$123.30K
순이익/손실:
$-11.95M
주가수익비율:
-0.5446
EPS:
-1.5421
순현금흐름:
$-12.57M
1주 성능:
+31.66%
1개월 성능:
+37.36%
6개월 성능:
-8.04%
1년 성능:
-46.81%
1일 변동 폭
$0.8202
$0.9099
1주일 범위
$0.6801
$1.16
52주 변동 폭
$0.548
$1.69
Aprea Therapeutics Inc Stock (APRE) Company Profile
명칭
Aprea Therapeutics Inc
전화
215-948-4119
주소
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
0.8384 | 8.06M | 123.30K | -11.95M | -12.57M | -1.5421 |
VRTX
Vertex Pharmaceuticals Inc
|
542.68 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
790.76 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,028.30 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.02 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
206.40 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-12-28 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-06-22 | 개시 | H.C. Wainwright | Neutral |
| 2020-04-21 | 개시 | Robert W. Baird | Outperform |
| 2019-10-28 | 개시 | JP Morgan | Neutral |
| 2019-10-28 | 개시 | Morgan Stanley | Equal-Weight |
| 2019-10-28 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Aprea Therapeutics Inc 주식(APRE)의 최신 뉴스
Aprea Expands Cancer Trial as APR-1051 Shows Early Activity - MyChesCo
Aprea (APRE) Technical Snapshot: Slides 2.03% to $0.68 for the Current Session; Session Range View: Price Remains Between $0.65 Support and $0.71 Resistance under the Current SnapshotChandelier Stop - vinanet.vn
APRE Q1 2026 Earnings: Narrower-than-Expected Loss Signals Disciplined ExecutionEarnings Recovery Stocks - Vinanet
Aprea Therapeutics (APRE) Edges Higher by 1.34% as Shares Hover Above Key SupportStrangle Setup - vinanet.vn
Maxim Group Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Aprea Therapeutics (APRE) Consolidates Near Support as Shares Dip 1.76%Mid Cap Momentum - vinanet.vn
Oppenheimer Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Aprea Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Aprea Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Aprea Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Aprea Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
APRE: APR-1051 demonstrates promising early efficacy and safety, driving a biomarker-focused oncology pipeline - TradingView
Aprea Therapeutics advances APR-1051 oncology pipeline progress - TipRanks
Form 8K Aprea Therapeutics Inc For: 12 August - Investing.com India
Aprea Therapeutics 2Q 2026: Revenue $0 Net loss $(3.59M), EPS $(0.07) — 10-Q Summary - TradingView
Aprea Therapeutics (NASDAQ: APRE) extends cash runway with $41M balance and trial updates - Stock Titan
Aprea Therapeutics Announces Second Quarter 2026 Financial Results - The Manila Times
Aprea Therapeutics Reports $3.6 Million Q2 Net Loss - Quiver Quantitative
Aprea Therapeutics Q2 net loss widens on higher R&D costs - TradingView
Aprea Therapeutics Inc (APRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Price to earnings forward of Aprea Therapeutics, Inc. – NASDAQ:APRE - TradingView
Aprea Therapeutics Inc (APRE) Stock News Today - TradingKey
Aprea Therapeutics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Aprea Therapeutics, Inc. (APRE) stock price, news, quote and history - Yahoo Finance Singapore
Aprea Expands APR-1051 Trial as Enrollment Accelerates - mychesco.com
APRE Q2'26 Earnings: EPS estimate is (0.18) USD - TradingView
Aprea’s ATRN-119 Trial Completion: What It Means For APRE Investors - TipRanks
APRE Q1 2026 Earnings: Narrower-than-Expected Loss Beats Estimates, Shares Slide 2.36%High Growth Earnings - dars.gov.et
Aprea Therapeutics plans Q4 2026 data update for APR-1051 trial - Investing.com Nigeria
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026 - The Manila Times
Q&A: Aprea Therapeutics' Oren Gilad on WEE1 Inhibitor Data and the Company's DNA Damage Response Strategy - BioPharm International
Aprea Therapeutics Inc (APRE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aprea Therapeutics Inc (APRE) Institutional Confidence - TradingKey
APRE|Aprea Therapeutics Inc|Price:0.620|Chg%:-0.012 - TradingKey
Aprea Therapeutics Inc (APRE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aprea Therapeutics Inc (APRE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Aprea Therapeutics Inc (APRE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
APRE|Aprea Therapeutics Inc|Price:0.632|Chg%:+0.004 - TradingKey
Aprea Therapeutics Inc (APRE) Cash Flow - TradingKey
Aprea Therapeutics (NASDAQ: APRE) wins 180-day extension to meet $1 bid - Stock Titan
Aprea Therapeutics (APRE) Edges Higher with Modest Gains Amid Tight Trading RangeMedian Line - dars.gov.et
Aprea Therapeutics(APRE) Stock Options Chain | Quotes & News - Moomoo
Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial - Stocktwits
Enterprise value to EBITDA forward of Aprea Therapeutics, Inc. – NASDAQ:APRE - TradingView
APRE Forecast — Price Target — Prediction for 2027 - TradingView
Aprea Therapeutics, Inc. Actuals & Estimates (NASDAQ:APRE) - TradingView
Precision Medicine Strategies Expand Opportunities for Targeted Cancer Treatment, Says Dr Oren Gilad, Aprea Therapeutics - BioPharm International
Aprea Shareholders Approve Directors, Reverse Split Flexibility - The Globe and Mail
Aprea Therapeutics Inc (APRE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aprea Therapeutics Shareholders Approve Reverse Stock Split and Key Proposals at 2026 Annual Meeting - Minichart
Aprea Therapeutics Inc (APRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
7.55%
자본화:
|
볼륨(24시간):